A compound of Formula a tautomer or a stereoisomeric form thereof, wherein R 3 is selected from the group consisting of hydrogen, C 1-4 alkyloxy, cyano and Het 1; A 1 is CR 4a or N; wherein R 4a is hydrogen, halo or C 1-4 alkyloxy optionally substituted with one or more substituents selected from the group consisting of C 1-4 alkyloxy and halo; A 2 is CR 4b or N; wherein R 4b is hydrogen, halo, C 1-4 alkyloxy, cyano or Het 2; A 3 is CR 4c or N; wherein R 4c is hydrogen, halo or C 1-4 alkyloxy; provided that maximum one of A 1, A 2 and A 3 is N; Het 1 and Het 2 each independently represent a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, imidazolyl, oxazolyl, 1,2,4-triazolyl and pyrazolyl; wherein said 5- or 6-membered heteroaryl may be substituted with one or more C 1-4 alkyl substituents; Y is N or CR a; wherein R a is hydrogen, halo or C 1-4 alkyl optionally substituted with one hydroxyl; X is N or CH; R 1 and R 2 are taken together to form a bivalent radical -R 1 -R 2 - having formula (b-1) or (b-2) - ( CH 2) m -Z-CH 2 - (b-1); -CH 2 -Z-(CH 2) m - (b-2); m represents 2, 3 or 4; Z represents a direct bond, NR 5 or O; wherein R 5 is hydrogen, C 1-4 alkylcarbonyl, Ar 1, (C=O)-Ar 1 or C 1-4 alkyl optionally substituted with one or more fluoro substituents; wherein (b-1) or (b-2) is substituted on one or more CH 2 groups with one or two substituents each independently selected from the group consisting of Ar 2, (C=O)-Ar 2, O-Ar 2, NR 6 -Ar 2, C 1-4 alkylcarbonyl, fluoro, hydroxy, and C 1-4 alkyl optionally substituted with one or more fluoro substituents; each Ar 1 and Ar 2 independently represents phenyl, pyrazolyl or pyridinyl; wherein said phenyl, pyrazolyl or pyridinyl may be substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR 7 R 8, morpholinyl, cycloC 3-7 alkyl, C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkyloxy, fluoro and cycloC 3-7 alkyl, and C 1-4 alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of fluoro and cycloC 3-7 alkyl; each R 6 independently is hydrogen, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of fluoro and cycloC 3-7 alkyl; each R 7 independently is hydrogen, C 1-4 alkyl or C 1-4 alkylcarbonyl; each R 8 independently is hydrogen or C 1-4 alkyl; or a pharmaceutically acceptable addition salt or a solvate thereof. a tautomer or a stereoisomeric form thereof, wherein R 3 is selected from the group consisting of hydrogen, C 1-4 alkyloxy, cyano and Het 1; A 1 is CR 4a or N; wherein R 4a is hydrogen, halo or C 1-4 alkyloxy optionally substituted with one or more substituents selected from the group consisting of C 1-4 alkyloxy and halo; A 2 is CR 4b or N; wherein R 4b is hydrogen, halo, C 1-4 alkyloxy, cyano or Het 2; A 3 is CR 4c or N; wherein R 4c is hydrogen, halo or C 1-4 alkyloxy; provided that maximum one of A 1, A 2 and A 3 is N; Het 1 and Het 2 each independently represent a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, imidazolyl, oxazolyl, 1,2,4-triazolyl and pyrazolyl; wherein said 5- or 6-membered heteroaryl may be substituted with one or more C 1-4 alkyl substituents; Y is N or CR a; wherein R a is hydrogen, halo or C 1-4 alkyl optionally substituted with one hydroxyl; X is N or CH; R 1 and R 2 are taken together to form a bivalent radical -R 1 -R 2 - having formula (b-1) or (b-2) - ( CH 2) m -Z-CH 2 - (b-1); -CH 2 -Z-(CH 2) m - (b-2); m represents 2, 3 or 4; Z represents a direct bond, NR 5 or O; wherein R 5 is hydrogen, C 1-4 alkylcarbonyl, Ar 1, (C=O)-Ar 1 or C 1-4 alkyl optionally substituted with one or more fluoro substituents; wherein (b-1) or (b-2) is substituted on one or more CH 2 groups with one or two substituents each independently selected from the group consisting of Ar 2, (C=O)-Ar 2, O-Ar 2, NR 6 -Ar 2, C 1-4 alkylcarbonyl, fluoro, hydroxy, and C 1-4 alkyl optionally substituted with one or more fluoro substituents; each Ar 1 and Ar 2 independently represents phenyl, pyrazolyl or pyridinyl; wherein said phenyl, pyrazolyl or pyridinyl may be substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR 7 R 8, morpholinyl, cycloC 3-7 alkyl, C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkyloxy, fluoro and cycloC 3-7 alkyl, and C 1-4 alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of fluoro and cycloC 3-7 alkyl; each R 6 independently is hydrogen, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of fluoro and cycloC 3-7 alkyl; each R 7 independently is hydrogen, C 1-4 alkyl or C 1-4 alkylcarbonyl; each R 8 independently is hydrogen or C 1-4 alkyl;